Sound journalism, grounded in facts and Biblical truth | Donate

Johnson & Johnson recommends booster shot

A vial of the COVID-19 vaccine produced by Johnson & Johnson Associated Press/Photo by Mary Altaffer (file)

Johnson & Johnson recommends booster shot

A second dose of the J&J/Janssen COVID-19 vaccine can be 94 percent effective against symptomatic infection, the company reported Tuesday. A booster administered six months after the first dose showed a 12-fold increase in antibodies, according to data from a late-stage clinical trial. The data has not been published in a journal or peer-reviewed yet, but the company sent it to the U.S. Food and Drug Administration and the European Medicines Agency for review and possible approval.

What do the numbers mean? J&J is basing its recommendation on a trial involving 32,000 adult participants in 10 countries, including the United States. The booster shot showed 75 percent protection against severe infection, with 94 percent effectiveness for U.S. participants. J&J did not say why the rates are different, but it might be due to different variants circulating in other countries.

Dig deeper: Read John Dawson’s report in Beginnings about J&J vaccine side effects.

Carolina Lumetta

Carolina is a reporter for WORLD Digital. She is a World Journalism Institute and Wheaton College graduate. She resides in Harrisburg, Pa.



Please wait while we load the latest comments...


Please register or subscribe to comment on this article.


This is "science by press release". Not only has this not been peer reviewed nor published as you point out. It has not been officially been evaluated by the FDA. This is another reason why we are so skewed on these issues. Biden promised a September 20 roll out of a booster before formal FDA approval. The politics of pandemics will need to be taught in Med School and university settings. That will be an interesting course to take. It should also be required for any Journalism or Political Science majors! These headlines are good for the stock prices for the companies touting their non-published nor evaluated data.